Healthcare provider profile · identity verified

Michael Paul Van Scoy, MD

Internal Medicine · HARRISBURG, PA · NPI 1780842849

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	467	78
Amlodipine Besylate	Amlodipine Besylate	407	69
Pantoprazole Sodium	Pantoprazole Sodium	223	43
Gabapentin	Gabapentin	220	52
Levothyroxine Sodium	Levothyroxine Sodium	213	41
Lisinopril	Lisinopril	213	46
Potassium Chloride	Potassium Chloride	169	27
Furosemide	Furosemide	157	31
Omeprazole	Omeprazole	152	34
Metformin Hcl	Metformin Hcl	151	30
Albuterol Sulfate Hfa	Albuterol Sulfate	135	52
Carvedilol	Carvedilol	101	21
Metoprolol Succinate	Metoprolol Succinate	99	25
Eliquis	Apixaban	97	23
Simvastatin	Simvastatin	87	12
Fenofibrate	Fenofibrate Nanocrystallized	83	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	83	16
Fluticasone Propionate	Fluticasone Propionate	81	25
Losartan Potassium	Losartan Potassium	76	17
Tamsulosin Hcl	Tamsulosin Hcl	76	17
Hydralazine Hcl	Hydralazine Hcl	74	17
Oxybutynin Chloride Er	Oxybutynin Chloride	72	suppressed
Famotidine	Famotidine	68	13
Sertraline Hcl	Sertraline Hcl	68	19
Levetiracetam	Levetiracetam	66	15
Meloxicam	Meloxicam	65	16
Montelukast Sodium	Montelukast Sodium	59	11
Warfarin Sodium	Warfarin Sodium	59	12
Clopidogrel	Clopidogrel Bisulfate	58	11
Jardiance	Empagliflozin	55	11
Bumetanide	Bumetanide	54	16
Hydrochlorothiazide	Hydrochlorothiazide	52	12
Quetiapine Fumarate	Quetiapine Fumarate	51	15
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	48	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	47	suppressed
Pravastatin Sodium	Pravastatin Sodium	46	suppressed
Oxycodone Hcl	Oxycodone Hcl	45	suppressed
Fenofibrate	Fenofibrate	42	suppressed
Pregabalin	Pregabalin	41	11
Tizanidine Hcl	Tizanidine Hcl	41	suppressed
Sucralfate	Sucralfate	39	suppressed
Buspirone Hcl	Buspirone Hcl	37	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	37	suppressed
Spironolactone	Spironolactone	37	11
Nystatin	Nystatin	36	12
Rosuvastatin Calcium	Rosuvastatin Calcium	36	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	35	suppressed
Olanzapine	Olanzapine	35	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	35	suppressed
Nifedipine Er	Nifedipine	34	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	34	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	33	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	33	suppressed
Baclofen	Baclofen	32	11
Diclofenac Sodium	Diclofenac Sodium	32	12
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Mirtazapine	Mirtazapine	30	11
Trazodone Hcl	Trazodone Hcl	30	13
Glipizide Er	Glipizide	29	suppressed
Ibuprofen	Ibuprofen	29	16
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	14
Prednisone	Prednisone	28	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Risperidone	Risperidone	27	suppressed
Clonazepam	Clonazepam	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	25	suppressed
Methenamine Hippurate	Methenamine Hippurate	25	suppressed
Ammonium Lactate	Ammonium Lactate	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Lamotrigine	Lamotrigine	23	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	23	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Haloperidol	Haloperidol	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Midodrine Hcl	Midodrine Hcl	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	17
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Latanoprost	Latanoprost	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Pen Needles	Pen Needle, Diabetic	19	suppressed
Ibu	Ibuprofen	18	suppressed
Lactulose	Lactulose	18	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Azithromycin	Azithromycin	16	11
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Hydrocortisone	Hydrocortisone	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Sotalol	Sotalol Hcl	15	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	14	suppressed
Divalproex Sodium Er	Divalproex Sodium	14	suppressed
Finasteride	Finasteride	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Glipizide	Glipizide	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Nyamyc	Nystatin	13	suppressed
Spiriva Handihaler	Tiotropium Bromide	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Dutasteride	Dutasteride	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Metolazone	Metolazone	12	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Benztropine Mesylate	Benztropine Mesylate	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Jantoven	Warfarin Sodium	11	suppressed
Klor-Con M20	Potassium Chloride	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error